Close Menu

NEW YORK — Genetron Health on Thursday reported a 40 percent year-over-year rise in revenues for the second quarter on strong sales from its cancer diagnosis and monitoring operations, which include lab-developed tests (LDTs) and in vitro diagnostics (IVDs).

Beijing-based Genetron, which went public in the US in June to raise $235.0 million, posted second quarter revenues of RMB101.7 million ($14.6 million) versus RMB72.5 million in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.